Trial Profile
Evaluation of the safety of the nasal administration of NeuroEPO in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Anaemia; Cardiovascular disorders; Cerebral infarction; Parkinson's disease
- Focus Adverse reactions
- 21 Jan 2016 New trial record